Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy of short-course versus standard-course blinatumomab in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

YZYile ZhouLMLiping MaoHTHongyan Tong

Discussion

Loading...

Member takes

Overview

Retrospective study finds similar survival outcomes with 14-day versus standard-course blinatumomab in B-ALL patients, suggesting treatment flexibility.

Key Points

  • Survival outcomes were comparable between the 14-day and >14-day courses of blinatumomab for patients with B-ALL.
  • With a median follow-up of 21.47 months, the median progression-free survival was 9.90 months for the 14-day cohort.
  • Retrospective cohort analysis assessed the efficacy of short-course blinatumomab in relapsed or refractory B-ALL patients.
  • No significant differences in toxicity or cytokine response syndrome were noted between the two treatment durations.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de67https://doi.org/10.1182/blood-2025-1562
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Short-term blinatumomab regimen in newly diagnosed induction and MRD-negative consolidation treatment of B-cell acute lymphoblastic leukemia2025 · 1 citations
  2. 2Updated results of A phase II study of blinatumomab in adults with measurable residual disease of 10-4 or higher2025
  3. 3The efficacy of short-course blinatumomab immunotherapy as a bridge-to-HSCT in ph-negative B-cell acute lymphoblastic leukemia2025
  4. 4Blinatumomab demonstrates MRD eradication in MRD-positive/chemotherapy-delayed pediatric B-ALL and high response in relapsed/refractory cases: a multicenter cohort study2025
  5. 5Blinatumomab efficacy differs between newly diagnosed and relapsed/refractory B-ALL: Impact on MRD clearance and survival2025